Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy

Judd E. Hollander, Robert S. Hoffman, Paul Gennis, Phillip Fairweather, Michael J. Disano, David A. Schumb, James A. Feldman, Susan S. Fish, Sophia Dyer, Paul Wax, Chris Whelan, Evan Schwarzwald

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The optimal medical regimen for the treatment of cocaine associated myocardial ischemia has not been defined. While animal and human data demonstrate the risks of beta-adrenergic blockade, studies in the cardiac catheterization laboratory suggest a beneficial role of nitroglycerin. We performed a prospective multicenter observational study to evaluate the clinical safety and efficacy of nitroglycerin in the treatment of cocaine associated chest pain at six municipal hospital centers. Of 246 patients presenting with cocaine associated chest pain, 83 patients were treated with nitroglycerin at the discretion of the treating physician. Relief of chest pain and/or adverse hemodynamic outcome were the primary endpoints. Baseline comparisons of patients treated with nitroglycerin to those not treated with nitroglycerin found that the treated patients were at higher risk of ischemic heart disease. They were older (36 years vs 32 years, p = 0.0008), more likely to have an ischemic electrocardiogram (27% vs 4% p < 0.0001), to be admitted (94% vs 40% p < 0.0001), and to have a discharge diagnosis of ischemic heart disease (41% vs 9% p < 0.0001). Nitroglycerin was beneficial in 41 patients (49%; 95% CI, 38-60%; 37 patients (45% had relief or reduction in the severity of chest pain and 4 patients (5% had other beneficial effects. Only one patient had an adverse outcome (translent hypotension in the setting of a right ventricular infarct). Nitroglycerin is safe and possibly effective in the treatment of cocaine associated chest pain.

Original languageEnglish (US)
Pages (from-to)243-256
Number of pages14
JournalClinical Toxicology
Volume32
Issue number3
DOIs
StatePublished - 1994

Fingerprint

Nitroglycerin
Chest Pain
Cocaine
Safety
Myocardial Ischemia
Therapeutics
Municipal Hospitals
Hemodynamics
Electrocardiography
Adrenergic Agents
Cardiac Catheterization
Hypotension
Animals
Multicenter Studies
Observational Studies
Physicians

Keywords

  • Angina
  • Cocaine
  • Drug abuse
  • Human
  • Ischemia
  • Myocardial infarction
  • Nitroglycerin

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Hollander, J. E., Hoffman, R. S., Gennis, P., Fairweather, P., Disano, M. J., Schumb, D. A., ... Schwarzwald, E. (1994). Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy. Clinical Toxicology, 32(3), 243-256. https://doi.org/10.3109/15563659409017957

Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy. / Hollander, Judd E.; Hoffman, Robert S.; Gennis, Paul; Fairweather, Phillip; Disano, Michael J.; Schumb, David A.; Feldman, James A.; Fish, Susan S.; Dyer, Sophia; Wax, Paul; Whelan, Chris; Schwarzwald, Evan.

In: Clinical Toxicology, Vol. 32, No. 3, 1994, p. 243-256.

Research output: Contribution to journalArticle

Hollander, JE, Hoffman, RS, Gennis, P, Fairweather, P, Disano, MJ, Schumb, DA, Feldman, JA, Fish, SS, Dyer, S, Wax, P, Whelan, C & Schwarzwald, E 1994, 'Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy', Clinical Toxicology, vol. 32, no. 3, pp. 243-256. https://doi.org/10.3109/15563659409017957
Hollander JE, Hoffman RS, Gennis P, Fairweather P, Disano MJ, Schumb DA et al. Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy. Clinical Toxicology. 1994;32(3):243-256. https://doi.org/10.3109/15563659409017957
Hollander, Judd E. ; Hoffman, Robert S. ; Gennis, Paul ; Fairweather, Phillip ; Disano, Michael J. ; Schumb, David A. ; Feldman, James A. ; Fish, Susan S. ; Dyer, Sophia ; Wax, Paul ; Whelan, Chris ; Schwarzwald, Evan. / Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy. In: Clinical Toxicology. 1994 ; Vol. 32, No. 3. pp. 243-256.
@article{6c299aa123d74ccf9c0c97b88d5f3272,
title = "Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy",
abstract = "The optimal medical regimen for the treatment of cocaine associated myocardial ischemia has not been defined. While animal and human data demonstrate the risks of beta-adrenergic blockade, studies in the cardiac catheterization laboratory suggest a beneficial role of nitroglycerin. We performed a prospective multicenter observational study to evaluate the clinical safety and efficacy of nitroglycerin in the treatment of cocaine associated chest pain at six municipal hospital centers. Of 246 patients presenting with cocaine associated chest pain, 83 patients were treated with nitroglycerin at the discretion of the treating physician. Relief of chest pain and/or adverse hemodynamic outcome were the primary endpoints. Baseline comparisons of patients treated with nitroglycerin to those not treated with nitroglycerin found that the treated patients were at higher risk of ischemic heart disease. They were older (36 years vs 32 years, p = 0.0008), more likely to have an ischemic electrocardiogram (27{\%} vs 4{\%} p < 0.0001), to be admitted (94{\%} vs 40{\%} p < 0.0001), and to have a discharge diagnosis of ischemic heart disease (41{\%} vs 9{\%} p < 0.0001). Nitroglycerin was beneficial in 41 patients (49{\%}; 95{\%} CI, 38-60{\%}; 37 patients (45{\%} had relief or reduction in the severity of chest pain and 4 patients (5{\%} had other beneficial effects. Only one patient had an adverse outcome (translent hypotension in the setting of a right ventricular infarct). Nitroglycerin is safe and possibly effective in the treatment of cocaine associated chest pain.",
keywords = "Angina, Cocaine, Drug abuse, Human, Ischemia, Myocardial infarction, Nitroglycerin",
author = "Hollander, {Judd E.} and Hoffman, {Robert S.} and Paul Gennis and Phillip Fairweather and Disano, {Michael J.} and Schumb, {David A.} and Feldman, {James A.} and Fish, {Susan S.} and Sophia Dyer and Paul Wax and Chris Whelan and Evan Schwarzwald",
year = "1994",
doi = "10.3109/15563659409017957",
language = "English (US)",
volume = "32",
pages = "243--256",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Dekker",
number = "3",

}

TY - JOUR

T1 - Nitroglycerin in the treatment of cocaine associated chest pain - Clinical safety and efficacy

AU - Hollander, Judd E.

AU - Hoffman, Robert S.

AU - Gennis, Paul

AU - Fairweather, Phillip

AU - Disano, Michael J.

AU - Schumb, David A.

AU - Feldman, James A.

AU - Fish, Susan S.

AU - Dyer, Sophia

AU - Wax, Paul

AU - Whelan, Chris

AU - Schwarzwald, Evan

PY - 1994

Y1 - 1994

N2 - The optimal medical regimen for the treatment of cocaine associated myocardial ischemia has not been defined. While animal and human data demonstrate the risks of beta-adrenergic blockade, studies in the cardiac catheterization laboratory suggest a beneficial role of nitroglycerin. We performed a prospective multicenter observational study to evaluate the clinical safety and efficacy of nitroglycerin in the treatment of cocaine associated chest pain at six municipal hospital centers. Of 246 patients presenting with cocaine associated chest pain, 83 patients were treated with nitroglycerin at the discretion of the treating physician. Relief of chest pain and/or adverse hemodynamic outcome were the primary endpoints. Baseline comparisons of patients treated with nitroglycerin to those not treated with nitroglycerin found that the treated patients were at higher risk of ischemic heart disease. They were older (36 years vs 32 years, p = 0.0008), more likely to have an ischemic electrocardiogram (27% vs 4% p < 0.0001), to be admitted (94% vs 40% p < 0.0001), and to have a discharge diagnosis of ischemic heart disease (41% vs 9% p < 0.0001). Nitroglycerin was beneficial in 41 patients (49%; 95% CI, 38-60%; 37 patients (45% had relief or reduction in the severity of chest pain and 4 patients (5% had other beneficial effects. Only one patient had an adverse outcome (translent hypotension in the setting of a right ventricular infarct). Nitroglycerin is safe and possibly effective in the treatment of cocaine associated chest pain.

AB - The optimal medical regimen for the treatment of cocaine associated myocardial ischemia has not been defined. While animal and human data demonstrate the risks of beta-adrenergic blockade, studies in the cardiac catheterization laboratory suggest a beneficial role of nitroglycerin. We performed a prospective multicenter observational study to evaluate the clinical safety and efficacy of nitroglycerin in the treatment of cocaine associated chest pain at six municipal hospital centers. Of 246 patients presenting with cocaine associated chest pain, 83 patients were treated with nitroglycerin at the discretion of the treating physician. Relief of chest pain and/or adverse hemodynamic outcome were the primary endpoints. Baseline comparisons of patients treated with nitroglycerin to those not treated with nitroglycerin found that the treated patients were at higher risk of ischemic heart disease. They were older (36 years vs 32 years, p = 0.0008), more likely to have an ischemic electrocardiogram (27% vs 4% p < 0.0001), to be admitted (94% vs 40% p < 0.0001), and to have a discharge diagnosis of ischemic heart disease (41% vs 9% p < 0.0001). Nitroglycerin was beneficial in 41 patients (49%; 95% CI, 38-60%; 37 patients (45% had relief or reduction in the severity of chest pain and 4 patients (5% had other beneficial effects. Only one patient had an adverse outcome (translent hypotension in the setting of a right ventricular infarct). Nitroglycerin is safe and possibly effective in the treatment of cocaine associated chest pain.

KW - Angina

KW - Cocaine

KW - Drug abuse

KW - Human

KW - Ischemia

KW - Myocardial infarction

KW - Nitroglycerin

UR - http://www.scopus.com/inward/record.url?scp=0028360329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028360329&partnerID=8YFLogxK

U2 - 10.3109/15563659409017957

DO - 10.3109/15563659409017957

M3 - Article

VL - 32

SP - 243

EP - 256

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 3

ER -